iCE Neuro: From Conception to Clinical Application
May 2024
iCE Neuro selected by MedTech Innovator program as one of five companies (out of more than 400 applicants) to the American Heart Association/MTI Heart and Brain Accelerator.
June 2023
First clinical use of iCE-SG2 electrodes.
December 2022
FDA grants 510k clearance for iCE-SG2 Subcutaneous Electrode Arrays.
December 2021
First clinical use of iCE-SG electrodes with the iCEWav Neuromonitoring Platform.
March 2021
FDA grants 510(k) clearance for iCE-SG Subcutaneous Electrode arrays.
November 2020
iCE Neuro completes landmark trial of iCE-SG electrodes in patients with cardiac arrest.
April 2020
FDA grants 510(k) clearance for the iCEWav Neuromonitoring software platform.
March 2020
FDA grants Emergency Use authorization for use of the iCEWav Neuromonitoring Platform with subcutaneous electrodes for a critically ill COVID patient.
May 2018
iCE Neuro launches to build a definitive technology platform that will solve the EEG challenge for critically ill patients.